The 2026 joint meeting of the German Center for Infection Research (DZIF) and Paul-Ehrlich Society for Infection Therapy (PEG) aims to address the complexity of infectious disease research and the necessity of interdisciplinary collaboration to combat the growing threats of drug resistance, and epidemic and pandemic events. Key topics include innovations in drug research, development, and application, the growing threat of antibiotic resistance, climate-sensitive infectious diseases, and the latest findings on interactions between hosts and pathogens.
Symposium
Progress and Challenges in Drug Discovery and Development
Date: Monday, 23 February 2026
Time: 11:00-12:10
| DNDi’s efforts in addressing health-related needs in neglected populations Laurent Fraisse, Research & Development Director, DNDi |
| Development of Corallopyronin A and Oxfendazole for the treatment of filarial infections Marc P. Hübner, DZIF Professor for Translational Microbiology, University of Bonn |
| Efficacy of Corallopyronin A against staphylococcal infections is based on a fCmax/MIC PK/PD driver Katharina Rox, Helmholtz Centre for Infection Research (HZI) |
| UNITE4TB – DECISION: A BTZ-043 phase IIB dose-ranging trial in combination with Bedaquiline and Delamanid Michael Hölscher, Ludwig Maximilians University |
